EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 ASX ANNOUNCEMENT 21 August 2026 ──────────────────────────────────────── EBR announces transition of Chief Commercial Officer Santa Clara, California; 21 August 2026: EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), developer of the world’s only wireless cardiac pacing device for heart failure, today announced the impending departure of Erik Strandberg, Chief Commercial Officer, who will be leaving the Company in the coming months. During Mr. Strandberg’s transition out, President and CEO John McCutcheon will assume responsibility for the commercial organization as a search is conducted to identify a replacement Chief Commercial Officer. The Company does not expect any negative impact on US commercial adoption because of this change. During this period the Company will focus on accelerating outstanding training requirements in the field team to ensure there is capacity to support ongoing and increasing clinical demand for WiSE. John McCutcheon, EBR Systems’ President & Chief Executive Officer said: “We thank Erik for his significant contributions to EBR, particularly his efforts to build a best-i…
Open exhibit ↗Current Report · Items 5.02, 8.01, 9.01 · 8-K
EBR Systems, Inc.
EBRCZOTCEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Other Events
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Transition of Chief Commercial Officer On August 21, 2026, EBR Systems, Inc.…
Press release in this filing
EBR announces transition of Chief Commercial Officer →Company context
Silicon Valley-based EBR Systems (ASX:EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.